News | March 30, 2010

Next-Generation Coronary Stent Launched in Europe

March 30, 2010 – A new coronary stent recently launched in Europe is designed to gain easier access to distal lesions and help restore the artery's natural form.

Cordis Corp. launched the Presillion Plus next-generation bare metal stent system. An upgraded delivery system increases the speed of procedures with atraumatic delivery, increased pushability and smoother withdrawal.

The stent uses a new hypotube for improved pushability in crossing calcified lesions and a redesigned semicompliant balloon for precise stent deployment and decreased deflation time.

It is available in lengths from 8 to 33 mm including a new 28 mm addition, and in diameters from 2.5 to 4 mm.

The PIONIR study, designed to measure the safety and effectiveness of Presillion and Presillion Plus, completed enrollment at 16 sites in Europe and Israel. The study, conducted by Medinol, includes 278 patients and will evaluate clinical performance through one year.

For more information:

Related Content

Biotronik, PRO-Kinetic Energy cobalt chromium coronary stent system, FDA approval
Technology | Stents Bare Metal| February 15, 2017
The PRO-Kinetic Energy Cobalt Chromium (CoCr) Coronary Stent System from Biotronik has gained U.S. Food and Drug...
Biotronik Astron stent
Technology | Stents Peripheral| December 31, 2015
December 31, 2015 - The U.S.
Technology | Stents Bare Metal| December 09, 2015
Medinol U.S. recently opened their commercial business in Parsippany, New Jersey, followed by the launch of the...
News | Antiplatelet and Anticoagulation Therapies| June 11, 2015
Patients who received a bare metal coronary stent did not display significant differences in rates of adverse events...
Technology | July 22, 2014
July 22, 2014 — Boston Scientific announced it received U.S. Food and Drug Administration (FDA) approval for the Rebel...
Boston Scientific Rebel Platinum Chromium Coronary Stent System Bare Metal
News | March 13, 2014
Boston Scientific Corp. received CE marking for the Rebel Platinum Chromium Coronary Stent System, the company's latest...
Biosensors BioMatrix

The LEADERS Trial showed that the Biosensors BioMatrix, a drug-eluting stent with a biodegradable abluminal polymer coating, was functionally equivalent to a regular nonbiodegradable stent.

Feature | February 04, 2013 | Kamran Zamanian, Ph.D.
The interventional cardiology market includes, but is not limited to, drug-eluting stents, bare-metal stents,...
News | December 27, 2012
December 27, 2012 — Biotronik announced that the first implant has taken place in the BIOHELIX-I trial in the United...
Overlay Init